On The Radar – 19th Edition
By
The global pharmaceutical market continues to expand, fueled by specialty drugs, biologics, and an aging population. But rising R&D costs, patent expirations, and regulatory pressure are reshaping how growth is achieved.
➡ Why it matters: Growth isn’t slowing, but it’s getting more complex and more expensive.
Pharma pipelines are narrowing as companies prioritize high-impact therapies and abandon broad, less profitable research. Precision is replacing scale.
➡ Why it matters: Future therapies will be more targeted and higher cost, concentrating financial risk.
Pharmacy benefits are shifting toward pass-through models and away from hidden revenue streams. Employers are gaining clearer visibility into true drug costs.
➡ Why it matters: Transparency is no longer optional. It is becoming the foundation of benefit strategy.
Research shows anti-kickback penalties often fall short of the profits generated, raising questions about whether current enforcement mechanisms are effective.
➡ Why it matters: Misaligned incentives persist when accountability doesn’t outweigh financial gain.
Stop-loss carriers are increasingly “lasering” high-cost members, pushing more financial exposure onto self-funded plans as specialty drug costs rise.
➡Why it matters: Predictable high-cost claims are becoming the employer’s problem to solve.
Healthcare affordability challenges persist despite reform efforts, with systemic issues like patent strategies and intermediary incentives continuing to drive costs upward.
➡Why it matters: Structural issues require structural solutions, not surface-level fixes.
Facing patent cliffs and funding constraints, large pharma companies are acquiring biotech firms to sustain their pipelines rather than relying solely on internal R&D.
➡Why it matters: Innovation is consolidating, and competition dynamics are shifting.
Oral GLP-1 medications could increase adherence and demand, but may also accelerate utilization and overall spend for employer plans.
➡ Why it matters: Convenience drives utilization, and utilization drives cost.
Federal and state policymakers are doubling down on PBM reform, targeting spread pricing and mandating rebate pass-through to align incentives.
➡ Why it matters: The pressure for a more accountable supply chain is intensifying.
Proposed federal transparency rules would require deeper disclosure into PBM compensation and pricing practices, reinforcing fiduciary expectations.
➡ Why it matters: Visibility into the system increases legal and financial responsibility for plan sponsors.
Final Thoughts
The pharmacy landscape is moving toward a more transparent, more regulated, and more strategically managed future. But as visibility increases, so does complexity and employer responsibility. Organizations that actively engage with their data, partners, and contracts will be better equipped to navigate what comes next.
We’ll be back in two weeks with more news you need to know. If you’d like a custom analysis or want to explore SHARx program options for your clients, contact us!
Stay Connected with SHARx
Subscribe to our newsletter for monthly updates from our CEO, curated industry news, insights from our in-house pharmacist, the latest blog posts, and more. Just fill out the form to stay informed.
Newsletter Sign-up
Be the first to learn what’s new with SHARx.